ESCRS - PO1054 - Visual Outcomes In Open Angle Glaucoma Patients Implanted With A Wavefront-Shaping Presbyopia Correcting Iol

Visual Outcomes In Open Angle Glaucoma Patients Implanted With A Wavefront-Shaping Presbyopia Correcting Iol

Published 2023 - 41st Congress of the ESCRS

Reference: PO1054 | Type: Free paper | DOI: 10.82333/nf6a-yj89

Authors: Miguel Angel Teus* 1 , Esther Arranz Marquez 2 , Caridad Perez Vives 3

1Novovision,Madrid,Spain;Ophthalmology,Universidad de Alcala,Alcala de Henares,Spain, 2Novovision,Madrid,Spain, 3Alcon Vision,Geneva,Switzerland

Purpose

To report visual acuity, patient’s satisfaction, spectacle independence and visual disturbances in subjects with mild glaucoma implanted bilaterally with AcrySof IQ Vivity or/and AcrySof IQ Vivity Toric IOL.

Setting

Sub-group analysis of a multicenter, ambispective registry study conducted in Europe, Australia and New Zealand evaluating the performance of subjects with mild open angle glaucoma and bilaterally implanted with AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric IOL in a real world setting.

Methods

At the study entry visit, between 3-6 months after the 2nd eye surgery, binocular uncorrected and distance corrected visual acuities at distance, intermediate (66 cm) and near (40 cm) were measured (UCDVA/BCDVA, UCIVA/DCIVA and UCNVA/DCNVA).
Patient reported outcomes were also evaluated through validated questionnaires, such as Catquest SF-9 for patient’s satisfaction and IOLSAT for spectacle independence. 

Results

This final sub-analysis includes 35 subjects diagnosed with mild open angle glaucoma and bilaterally implanted with AcrySof IQ Vivity IOL. At study entry visit binocular mean logMAR (SD) UCDVA, UCIVA and UCNVA were 0.007 (0.112), 0.097 (0.125) and 0.283 (0.128), respectively. Binocular mean logMAR (SD) BCDVA, DCIVA and DCNVA were -0.038 (0.098), 0.091 (0.107) and 0.304 (0.114), respectively. Most of the subjects reported never using spectacles for far away (94.3%), arm’s length (91.4%) and up close (48.6%). More than 80% of the subjects reported no difficulty with their sight at their everyday life and 85.2% reported to be satisfied with their sight. 

Conclusions

This subgroup analysis shows excellent outcomes in glaucoma patients implanted with AcrySof IQ Vivity IOL, obtaining 20/20 Snellen visual acuity for distance, 20/25 for intermediate and 20/32 for near. Patient satisfaction was high as well as spectacle independence specially for distance and intermediate. Visual disturbances were very low with over 90% of the subjects reporting no unwanted visual effects.